Conference Track

Acute Leukemias

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

In AML, Complete Response, Strictly Defined, Predicts Increased Long-term Survival After Cytarabine Induction
High-Dose Pediatric Regimens Feasible in Adult ALL
Patients With AML Often Do Not Opt for Consolidation Recombinant IL-2, Despite Possible Therapeutic Benefit
In AML, Idarubicin Induction Produces More CRs Than High-Dose Daunorubicin Whereas IL-2 in Maintenance Therapy Offers No Clear Survival Benefit
Imatinib Added to HyperCVAD Demonstrates Favorable 3-Year DFS and OS in Acute Lymphoblastic Leukemia
CD20 Expression Associated With Poor Outcome in Adult Patients With B-Cell Precursor ALL
Rituximab-Containing Modified HyperCVAD Regimen Improves DFS in CD20-Positive Younger Adult Patients With ALL
ASCT—Whether From Siblings or Unrelated Donors—Benefits Patients With High-Risk AML in First CR
Dose-Intense Pediatric Regimen May Improve Outcomes in Adults With Newly Diagnosed ALL
Addition of Imatinib Did Not Affect Survival in Patients With Ph-Positive ALL in Preliminary Analysis of UK Study

Expert Analysis

Acute Leukemias

Program Director:
Roy A. Beveridge, MD

Faculty:
Dan Douer, MD Stephen J. Forman, MD Hagop M. Kantarjian, MD

Moderator:
Mark Kirschbaum, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new data about the selection of anthracycline antibiotics in induction treatment of acute myeloid leukemia
Explain how recent data on allogeneic stem cell transplantation in patients with acute myeloid leukemia may influence clinical practice
Identify the possible benefits and risks of using pediatric chemotherapy regimens in adult patients with acute lymphoblastic leukemia
Summarize the role of imatinib in regimens used to treat acute lymphoblastic leukemia
Discuss the significance of CD20 expression in prognosis and treatment of acute lymphoblastic leukemia

CME CREDIT INFORMATION

Release Date: 02/26/08

Expiration Date: 02/25/09

Physicians: maximum of 1 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.2 contact hours (0.12 CEUs)

Registered Nurses: 1.2 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.